FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+22.29%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$1.01B
AUM Growth
+$1.01B
(-18%)
Cap. Flow
+$4.8M
Cap. Flow
% of AUM
0.48%
Top 10 Holdings %
Top 10 Hldgs %
80.48%
Holding
18
New
3
Increased
1
Reduced
3
Closed
1
Top Buys
| 1 |
Scholar Rock
SRRK
|
$84.8M |
| 2 |
AnaptysBio
ANAB
|
$24.1M |
| 3 |
Inhibikase Therapeutics
IKT
|
$19.9M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$3.1M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$75.4M |
| 2 |
Nuvalent
NUVL
|
$28.9M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$20M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$2.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$6.05B
| $124M | 12.36% | 1,468,983 -891,094 | -38% | -$75.4M |
|
|
2
Nuvalent
NUVL
$5.52B
| $103M | 10.25% | 1,317,664 -369,400 | -22% | -$28.9M |
|
3
Spyre Therapeutics
SYRE
$996M
| $93.5M | 9.3% | 4,018,101 | – | – |
|
4
Apogee Therapeutics
APGE
$2.17B
| $92.8M | 9.23% | 2,048,647 | – | – |
|
|
5
Scholar Rock
SRRK
$3.14B
| $84.8M | 8.43% | +1,962,953 | New | +$84.8M |
|
6
Enliven Therapeutics
ELVN
$1.2B
| $72.1M | 7.16% | 3,202,798 | – | – |
|
7
Viridian Therapeutics
VRDN
$1.5B
| $66.1M | 6.57% | 3,445,813 | – | – |
|
|
ORKA
8
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $65.4M | 6.5% | 3,371,922 +160,000 | +5% | +$3.1M |
|
9
Dianthus Therapeutics
DNTH
$759M
| $58.9M | 5.85% | 2,700,691 | – | – |
|
10
Cogent Biosciences
COGT
$1.69B
| $48.6M | 4.83% | 6,225,641 | – | – |
|
|
11
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $43.4M | 4.32% | 2,194,341 -1,010,500 | -32% | -$20M |
|
12
Day One Biopharmaceuticals
DAWN
$769M
| $39.3M | 3.91% | 3,103,448 | – | – |
|
13
Astria Therapeutics
ATXS
$349M
| $31.8M | 3.16% | 3,554,129 | – | – |
|
|
14
AnaptysBio
ANAB
$569M
| $24.1M | 2.39% | +1,816,466 | New | +$24.1M |
|
|
BCAX
15
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $22.4M | 2.22% | 1,284,169 | – | – |
|
|
16
Inhibikase Therapeutics
IKT
$134M
| $19.9M | 1.98% | +6,125,000 | New | +$19.9M |
|
|
ZBIO
17
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $15.5M | 1.54% | 1,892,806 | – | – |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$511M
| – | – | -123,538 | Closed | -$2.8M |
|